Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, and acellular pertussis vaccine (Shenzhen Kangtai Biological Products)
- Development stage
- Unknown
- Lead developer
- Shenzhen Kangtai Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular diphtheria, tetanus, and pertussis (DTaP) vaccine is a combination biologic developed by Shenzhen Kangtai Biological Products (Biokangtai) for active immunization against diphtheria, tetanus, and whooping cough (pertussis). The formulation consists of purified diphtheria and tetanus toxoids along with acellular pertussis antigens (typically including pertussis toxoid, filamentous hemagglutinin, and pertactin) adsorbed onto an aluminum-based adjuvant to enhance the immune response. As an acellular vaccine, it utilizes specific purified proteins rather than whole-cell Bordetella pertussis, which is associated with a lower incidence of local and systemic adverse reactions. The vaccine is currently in Phase 3 clinical trials in China, specifically targeting the infant and pediatric population to provide protective antibody titers against Corynebacterium diphtheriae, Clostridium tetani, and Bordetella pertussis.
- Other names
- adsorbed acellular diphtheria, tetanus, and pertussis vaccineDTaP vaccineAdsorbed acellular DTP (component) combined vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria, tetanus, and acellular pertussis vaccine (Shenzhen Kangtai Biological Products).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, and acellular pertussis vaccine (Shenzhen Kangtai Biological Products).